Adults with mild-to-moderate atopic dermatitis (AD) with moderate-to-severe itch for at least 12 months are needed for a clinical research trial.
Eligible participants must have AD involvement of no more than 20% their body surface area (BSA) – roughly equivalent in size to 20 palm prints.
Eligible participants must also have a Body Mass Index (BMI) of no more than 40kg/m2, not have an immunodeficiency or be immunocompromised,
and apply their choice of non-prescription emollient daily to all areas where the study drug is not applied.
Participants may receive investigational medication or placebo during the double-blind treatment period. Study medication and study-related
assessments may be provided at no cost. If eligible, you will receive compensation for each completed study visit.
Study participation will last about 12 weeks and involve about 8 visits to the study center.
Mason - Dermatologists of Southwest Ohio
Similar Trials
No Similar Trials FoundThe following information is from ClinicalTrials.gov
Last Update Posted: September 24, 2023
NCT05870865
TrialSpark
Brief Summary:
The goal of this clinical trial is to evaluate ASN008 in people with itch caused by eczema. The main questions it aims to answer are: What is the efficacy and safety of ASN008? What is the impact of ASN008 on itch in patients with atopic dermatitis? Participants will be asked to apply topical ASN008, or matching vehicle (placebo containing no active drug), to their eczema lesions twice daily for 4 weeks. Researchers will compare 3 different doses of ASN008 and a matching vehicle group to see which group responds best.
Condition or Disease:
Dermatitis, Atopic
Intervention/Treatment:
Drug: ASN008Phase:
Phase 2
Ages Eligible for Study:
18 Years and older (Adult)
Sexes Eligible for Study:
All
Inclusion Criteria:
Male or female participants, 18 years or older, at the time of informed consent.
Diagnosis of mild to moderate AD for at least 12 months with no significant disease flares for at least 4 weeks before Screening (based upon medical chart, treating physician, or participant report with documented clinical confirmation by the Investigator)
Validated Investigator Global Assessment (vIGA) score of 2 or 3 at Day 1.
Body surface area (BSA) affected by AD ≤20% at Day 1.
Peak Pruritus NRS ≥7 at Day 1.
Body mass index (BMI) ≤40 kg/m2 at Screening.
Willingness to avoid pregnancy or fathering children.
Participant is willing to participate for the duration of the trial, comply with all trial procedures, and is capable of giving informed consent.
Exclusion Criteria:
Any female who is breastfeeding, pregnant, or who is planning to become pregnant during the trial.
Active infection requiring treatment, including skin infections (including clinically infected AD).
History of skin disease or presence of a skin condition that, in the opinion of the Investigator, would interfere with trial assessments.
Any clinically significant medical or psychiatric condition or physical/laboratory/ECG/vital signs abnormality that would, in the opinion of the Investigator, put the participant at undue risk or interfere with interpretation of trial results.
Use of any of the following treatments within the indicated washout period before Day 1:
Doxepin, hydroxyzine, or diphenhydramine use within 1 week prior to Day 1.
Use of topical product containing urea or any antihistamine within 1 week prior to Day 1.
Use of systemic antibiotic within 2 weeks, or topical antibiotics within 1 week, prior to Day 1.
Atopic dermatitis topical medication use within 2 weeks prior to Day 1, including, but not limited to, topical corticosteroids, crisaborole and any other topical phosphodiesterase-4 inhibitor, calcineurin inhibitors, JAK inhibitors, tars, bleach, antimicrobials, medical devices, and bleach or oatmeal baths.
Psoralen-UV-A or UV-B phototherapy (including tanning beds) or excimer laser within 4 weeks prior to Day
Systemic medication use including biologics that could affect AD less than 6 weeks prior to Day 1 (e.g., retinoids, calcineurin inhibitors, methotrexate, cyclosporine, hydroxycarbamide [hydroxyurea], azathioprine, oral/injectable corticosteroids), biologics and JAK inhibitors.
Known hypersensitivity to ASN008 or its excipients.
Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.
register now